A study presented at AMCP Nexus 2024 reveals that most patients with Alzheimer disease are not expected to reach the new Medicare Part D out-of-pocket maximum of $2000, potentially hindering access to high-cost treatments like lecanemab.
A study presented at AMCP Nexus 2024 reveals that most patients with Alzheimer disease are not expected to reach the new Medicare Part D out-of-pocket maximum of $2000, potentially hindering access to high-cost treatments like lecanemab.
Sean Chitwood, PharmD, MBA, Clinical Pharmacist, Medicare Stars & Clinical Quality, Government Programs at OptumRx, and Justin Bioc, PharmD, BCPS, BCGP, RPh, Head of Clinical Pharmacy at Devoted Health explored the complexities and nuances of...
Sean Chitwood, PharmD, MBA, Clinical Pharmacist, Medicare Stars & Clinical Quality, Government Programs at OptumRx, and Justin Bioc, PharmD, BCPS, BCGP, RPh, Head of Clinical Pharmacy at Devoted Health explored the complexities and nuances of...
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
"Advocacy and policy efforts directed towards increasing access to telehealth can ensure equitable and timely access to specialized cancer care in these regions of need," researchers said.
"Advocacy and policy efforts directed towards increasing access to telehealth can ensure equitable and timely access to specialized cancer care in these regions of need," researchers said.
Findings presented at AMCP 2022 showed the impact of a medication therapy management pilot program in Tennessee on cost savings, medication adherence, and members' resource utilization.
Findings presented at AMCP 2022 showed the impact of a medication therapy management pilot program in Tennessee on cost savings, medication adherence, and members' resource utilization.
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
The Centers for Medicare & Medicaid Services (CMS) has released its calendar year (CY) 2025 physician fee schedule proposals. In this commentary, an expert breaks down the key components and their implications for health care organizations.
The Centers for Medicare & Medicaid Services (CMS) has released its calendar year (CY) 2025 physician fee schedule proposals. In this commentary, an expert breaks down the key components and their implications for health care organizations.
With the 2024 elections just 13 days away, everyone has one question: What happens next? The stakes are particularly high for health policy, but there’s a cloud of uncertainty hanging over the predictions—especially when it comes to polling...
With the 2024 elections just 13 days away, everyone has one question: What happens next? The stakes are particularly high for health policy, but there’s a cloud of uncertainty hanging over the predictions—especially when it comes to polling...
Experts highlight the impact of the "warped incentives" in drug pricing's gross-to-net bubble, revealing that despite significant discounts, certain biosimilars are excluded from the formularies of major pharmacy benefit managers, leading to...
Experts highlight the impact of the "warped incentives" in drug pricing's gross-to-net bubble, revealing that despite significant discounts, certain biosimilars are excluded from the formularies of major pharmacy benefit managers, leading to...
Featuring Gary Owens, MD, president of Gary Owens Associates
Featuring Gary Owens, MD, presid...
Join us as guest expert Gary Owens discusses how formulary exclusions can impact patient medication adherence and lead to adverse economic outcomes, making the need for non-medical switching and formulary exception requests an important issue...
Join us as guest expert Gary Owens discusses how formulary exclusions can impact patient medication adherence and lead to adverse economic outcomes, making the need for non-medical switching and formulary exception requests an important issue...
A keynote session at AMCP 2024 outlined pharmaceutical industry trends and predictions for pharmacy benefits management (PBMs), including challenges and disruptors like the Inflation Reduction Act (IRA), changing consumer preferences, rising...
A keynote session at AMCP 2024 outlined pharmaceutical industry trends and predictions for pharmacy benefits management (PBMs), including challenges and disruptors like the Inflation Reduction Act (IRA), changing consumer preferences, rising...